Latest Anemia News
Intravenous iron should be strongly considered for patients treated with ESAs or hemodialysis, according to reviewers.
In type 2 diabetic male patients, a low testosterone level was found to be associated with anemia. These findings are consistent with previous reports.
Significantly more patients treated with ferric citrate increased their hemoglobin levels by 1 g/dL or more over 8 weeks.
The prevalence of low hemoglobin levels increases with declining renal function.
Ferric pyrophosphate citrate delivered via dialysate or intravenously rapidly donates iron to transferrin and is rapidly cleared from the circulation.
Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
Older men on TRT versus placebo for 1 year had improved hemoglobin levels and volumetric bone mineral density and estimated bone strength.
CKD patients with larger erythrocyte volumes had more than triple the risk of dying from cardiovascular causes, researchers reported.
Investigators observed no difference in hemoglobin level between transplant recipients and non-transplant CKD patients starting hemodialysis.
New and established peritoneal dialysis patients both showed this trend.
In a study 52.1% of patients receiving ferric citrate attained a 1.0 g/dL or greater increase in hemoglobin compared with just 19.1% receiving placebo.
New study finds no difference in all-cause and cause-specific mortality between iron sucrose and sodium ferric gluconate complex.
Use of ESAs declined while use of blood transfusions increased between 2008 and 2012.
The surface chemistry of the polymer reacts to the pH level of blood as it travels through the body.
The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.